Johnson & Johnson (NYSE:JNJ) on Tuesday posted upbeat earnings for the first quarter.

The company reported first-quarter 2025 adjusted earnings of $2.70 per share, down 2.5% year over year, beating the consensus of $2.67. The U.S. healthcare giant reported sales of $24.06 billion, up 9.9% year over year and beating the consensus of $23.63 billion.

Johnson & Johnson raised fiscal 2026 adjusted earnings guidance from $11.43-$11.63 per share to $11.45-$11.65, compared to the consensus of $11.54.

The company also revised fiscal 2026 sales guidance from $100 billion-$101 billion to $100.3 billion-$101.3 billion versus the consensus of $100.58 billion.

Johnson & Johnson shares fell 1.1% to trade at $237.35 on Wednesday.

These analysts made changes to their price targets on Johnson & Johnson following earnings announcement.

  • Wells Fargo analyst Larry Biegelsen maintained Johnson & Johnson with an Overweight rating and raised the price target from $240 to $263.
  • Stifel analyst Rick Wise maintained the stock with a Hold and raised the price target from $220 to $250.

Considering buying JNJ stock? Here’s what analysts think:

Photo via Shutterstock